Stifel upgraded Durect (NASDAQ:DRRX) to “buy” from “hold” and raised its price target to $3 from $1.25 and also transitioned coverage to Adam Walsh from Annabel Samimy. The stock closed at $1.59 on July 11.Read More
Canadian researchers created a simple blood test that can predict major heart-related complications after surgery.Read More
BTIG Research initiated research of Insulet (NASDAQ:PODD) and Intersect ENT (NASDAQ:XENT) with “neutral” ratings. Shares of Insulet closed at $32.21 and shares of Intersect at $13.51 on Tuesday.
Analyst Sean Lavin writes that he sees Insulet’s core business as fairly valued at five times next 12 months revenue as both the major upside events and key risks are hard to forecast in terms of timing.Read More
BTIG Research has initiated coverage of Entellus Medical (NASDAQ:ENTL) with a ‘buy” rating and $22 price target. The stock closed at $18.58 on Monday.
“Entellus Medical benefits patients, physicians, and payers by moving balloon sinus dilation (BSD) out of the hospital and into physician offices,” writes analyst Dr. Sean Lavin.Read More
Profound Medical (TSX-V:PRN) has made the first sale of its TULSA-PRO device to ResoFus Alomar in Barcelona, Spain.
Profound’s novel technology combines real-time magnetic resonance imaging with transurethral robotically driven ultrasound and closed-loop thermal feedback control, providing a highly precise treatment tailored to patient-specific anatomy and pathology.Read More
JMP Securities has resumed coverage of Novadaq Technologies (NASDAQ:NVDQ; TSX:NDQ) with a “market outperform” rating and $16 price target. The stock closed at $13.50 on Tuesday.
“Novadaq was once highly regarded within the small cap MedTech world, but its shares were driven down from historical highs by what we believe were overblown concerns around competition and a challenging transition to direct sales of SPY Elite, which is now in the company’s rearview mirror,” writes analyst John Gillings.Read More